Assessment of Serum Biomarkers associated with Vedolizumab Therapy Response in Inflammatory Bowel Disease.

被引：0
|
作者：
O'Connell, J. [1 ]
Argue, R. [1 ]
Dunne, M. [2 ]
O'Connell, F. [2 ]
Breslin, N. [3 ]
Cullen, G. [4 ]
Doherty, G. [4 ]
Dunne, C. [1 ]
Hartery, K. [1 ]
Ismail, M. S. [3 ]
MacCarthy, F. [1 ]
McDonagh, P. [1 ]
McKiernan, S. [1 ]
McNamara, D. [3 ]
Mulcahy, H. [1 ,4 ]
O'Connor, A. [3 ]
Ryan, B. [3 ]
Sheridan, J. [4 ]
O'Sullivan, J. [2 ]
Kevans, D. [1 ]
机构：
[1] St James Hosp, Gastroenterol, Dublin, Ireland
[2] Trinity Coll Dublin, Trinity Translat Med Inst, Surg, Dublin, Ireland
[3] Tallaght Univ Hosp, Gastroenterol, Dublin, Ireland
[4] St Vincents Univ Hosp, Gastroenterol, Dublin, Ireland
来源：
JOURNAL OF CROHNS & COLITIS | 2024年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P041
引用
收藏
页码：I299 / I299
页数：1
相关论文
共 50 条
  • [21] Effects of Vedolizumab Therapy on Extraintestinal Manifestations in Inflammatory Bowel Disease
    Mark Fleisher
    Jan Marsal
    Scott D. Lee
    Laura E. Frado
    Alyssa Parian
    Burton I. Korelitz
    Brian G. Feagan
    Digestive Diseases and Sciences, 2018, 63 : 825 - 833
  • [22] Effects of Vedolizumab Therapy on Extraintestinal Manifestations in Inflammatory Bowel Disease
    Fleisher, Mark
    Marsal, Jan
    Lee, Scott D.
    Frado, Laura E.
    Parian, Alyssa
    Korelitz, Burton I.
    Feagan, Brian G.
    DIGESTIVE DISEASES AND SCIENCES, 2018, 63 (04) : 825 - 833
  • [23] Therapeutic drug monitoring of vedolizumab therapy in inflammatory bowel disease
    Steenholdt, Casper
    Lorentsen, Ruben Due
    Petersen, Pernille Norgaard
    Widigson, Ella S. K.
    Kloft, Charlotte
    Klaasen, Rolf Anton
    Brynskov, Jorn
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2024, 39 (06) : 1088 - 1098
  • [24] VEDOLIZUMAB THERAPY FOR VERY EARLY ONSET INFLAMMATORY BOWEL DISEASE
    Shaul, Eliana
    Conrad, Maire A.
    Dawany, Noor
    Patel, Trusha
    Canavan, Megan C.
    Kelsen, Judith R.
    GASTROENTEROLOGY, 2022, 162 (07) : S1112 - S1112
  • [25] Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease
    Shmidt, Eugenia
    Kochhar, Gursimran
    Hartke, Justin
    Chilukuri, Prianka
    Meserve, Joseph
    Chaudrey, Khadija
    Koliani-Pace, Jenna L.
    Hirten, Robert
    Faleck, David
    Barocas, Morris
    Luo, Michelle
    Lasch, Karen
    Boland, Brigid S.
    Singh, Siddharth
    Vande Casteele, Niels
    Sagi, Sashidhar Varma
    Fischer, Monika
    Chang, Shannon
    Bohm, Matthew
    Lukin, Dana
    Sultan, Keith
    Swaminath, Arun
    Hudesman, David
    Gupta, Nitin
    Kane, Sunanda
    Loftus, Edward V., Jr.
    Sandborn, William J.
    Siegel, Corey A.
    Sands, Bruce E.
    Colombel, Jean-Frederic
    Shen, Bo
    Dulai, Parambir S.
    INFLAMMATORY BOWEL DISEASES, 2018, 24 (11) : 2461 - 2467
  • [26] Monoclonal antibody therapy of inflammatory bowel disease.
    S.J.H. van Deventer
    L. Camoglio
    Pharmacy World and Science, 1997, 19 : 55 - 59
  • [27] Modalities of corticosteroid therapy in inflammatory bowel disease.
    Sabate, JM
    Chaussade, S
    SEMAINE DES HOPITAUX, 1998, 74 (27-28): : 1079 - 1089
  • [28] Evolutionary biologic therapy for inflammatory bowel disease.
    Hanauer S.B.
    Current Gastroenterology Reports, 1999, 1 (6) : 467 - 469
  • [29] Trombopoietin serum levels in patients with inflammatory bowel disease.
    Kapsoritakis, AN
    Sfiridaki, A
    Potamianos, S
    Koukourakis, MI
    Roussomoustakaki, M
    Koutroubakis, IE
    Kouroumalis, EA
    GASTROENTEROLOGY, 1999, 116 (04) : A745 - A745
  • [30] VEDOLIZUMAB FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE
    Haddley, K.
    DRUGS OF TODAY, 2014, 50 (04) : 309 - 319
12345